| Document Date: 2012-10-12 16:03:22
Open Document File Size: 262,34 KBShare Result on Facebook
City Boston / / Company E.P. Cannon Paratek Pharmaceuticals Inc. / / / / MedicalCondition animal infection / serious Spn infections / Spn infection / chronic lung infection / systemic and organ-based infections / susceptible S. pneumoniae 157E infection S. pneumoniae / acute / lower respiratory tract infection / systemic S. pneumoniae infections / Immunocompetent (IC) Infection / infection / community-acquired pneumonia / S. pneumoniae infection / susceptible lower respiratory tract infection / susceptible and resistant lower respiratory tract infection / chronic lung model / Streptococcus pneumoniae Infections / acute lower respiratory tract infection / Neutropenia / resistant lower respiratory tract infection / susceptible systemic S. pneumoniae infection / resistant systemic S. pneumoniae infection / / MedicalTreatment antibiotics / / Person Thigh Wound (Neut) / Systemic / / / Position vivo model / / Product F-758 Abstract / Linezolid / cyclophosphamide / F-758 / / ProvinceOrState Massachusetts / /
SocialTag |
The Efficacy of PTK[removed]BAY[removed]in Murine Models of Streptococcus pneumoniae Infections *D. McKenney, J.M. Quinn, C.L. Jackson, J.L. Guilmet, J.A. Landry, S.K. Tanaka, and E.P. Cannon Paratek Pharmaceuticals, Inc.